Dr. Agarwal's Health Care Intrinsic Value
Dr. Agarwal's Health Care (AGARWALEYE) median intrinsic value is ₹462.50 from 9 valuation models (range ₹144–₹1199), vs current price ₹479.70 — -3.6% downside (Trading Near Calculated Value), margin of safety -3.7%. Browse Dr. Agarwal's Health Care financial data for revenue, profit, balance sheet and cash flow data.
AGARWALEYE Valuation Methods Summary — DCF, Graham Number & P/E
Dr. Agarwal's Health Care intrinsic value across 9 models vs current price ₹479.70 — upside/downside and value range per method. Also explore AGARWALEYE share price history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹143.91 | ₹115.13 - ₹172.69 | -70.0% | EPS: ₹3.76, Sector P/E: 12x |
| Book Value Method | asset | ₹602.19 | ₹541.97 - ₹662.41 | +25.5% | Book Value/Share: ₹602.19, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹507.00 | ₹456.30 - ₹557.70 | +5.7% | Revenue/Share: ₹633.75, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹959.40 | ₹863.46 - ₹1055.34 | +100.0% | EBITDA: ₹576.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1199.25 | ₹959.40 - ₹1439.10 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹143.91 | ₹129.52 - ₹158.30 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹143.91 | ₹129.52 - ₹158.30 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹462.50 | ₹416.25 - ₹508.75 | -3.6% | ROE: 7.7%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹225.71 | ₹203.14 - ₹248.28 | -52.9% | EPS: ₹3.76, BVPS: ₹602.19 |
AGARWALEYE Intrinsic Value vs Market Price — All Valuation Models
Dr. Agarwal's Health Care fair value range ₹144–₹1199 vs current market price ₹479.70 across 9 valuation models. For current market price and key ratios, visit AGARWALEYE stock price BSE.
AGARWALEYE Intrinsic Value Analysis — Undervalued or Overvalued?
Dr. Agarwal's Health Care median intrinsic value ₹462.50, current price ₹479.70 — Trading Near Calculated Value by 3.6%, margin of safety -3.7%.
What is the intrinsic value of AGARWALEYE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Dr. Agarwal's Health Care (AGARWALEYE) is ₹462.50 (median value). With the current market price of ₹479.70, this represents a -3.6% variance from our estimated fair value.
The valuation range spans from ₹143.91 to ₹1199.25, indicating ₹143.91 - ₹1199.25.
Is AGARWALEYE undervalued or overvalued?
Based on our multi-method analysis, Dr. Agarwal's Health Care (AGARWALEYE) appears to be trading near calculated value by approximately 3.6%.
AGARWALEYE Financial Health — Key Ratios vs Industry Benchmarks
Dr. Agarwal's Health Care financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.63 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 7.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.55x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AGARWALEYE Cash Flow Quality — Operating & Free Cash Flow
Dr. Agarwal's Health Care operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹360 Cr | ₹-15 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹346 Cr | ₹-111 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹233 Cr | ₹-22 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹164 Cr | ₹87 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹99 Cr | ₹76 Cr | Positive Free Cash Flow | 8/10 |